Hims Daily (Jun 27, 2025)
Will Novo pull the trigger and sue Hims?!
Today’s Hims Daily is brought to you by … Godel Terminal
People have tried to build a “Bloomberg killer” for years. Godel might actually pull it off. They’re just getting started, but what they’ve already built delivers 90% of Bloomberg’s functionality at 10% of the price. It’s a full trading terminal for $80/month.
We use it daily to track short interest, institutional ownership, analyst ratings, and earnings estimates. If you want access to the data powering Hims House (and a lot more) this is it. Sign up today to lock in lifetime access for $80/mo. First month just $60 if you sign up through Hims House 🔥
Stock Price: $49.43
Today: +$3.15 (+6.81%)
YTD: +$25.25 (+104.43%)
Q2: +$19.88 (+67.28%)
🚨 No Novo, No Problem. Yesterday we dropped a new Hims Data Tracker and Q2 revenue prediction. Momentum continues to build into the end of Q2. Upgrade to paid for access!
What’s Happening
SNAP-BACK RALLY ROLLS ON WITH HEAVY VOLUME. HIMS jumped +7% to $49.43, spiking near $52 intraday before pulling back.
80M shares were traded, roughly double the 90-day average 🤯
Squeeze dynamics intensify. IBKR’s borrow pool remains tight. For months, intraday availability has hovered around 4-5M shares. The past two sessions we’ve been in the mid-2Ms, even dipping below 2M at one point yesterday.
New CPO narrative still resonating. Hiring Dheerja Kaur (ex-Robinhood VP) continues to drive the “tech + product-led growth” thesis. Bulls are betting she’ll cement Hims’ identity as a tech company and help strengthen its positioning as the preeminent consumer-first healthcare company.
KOREA IS BACK ON THE MAP. HIMS is once again a top 50 stock in South Korea, hitting #31 on the weekly inflow list with $31.7M. It’s the highest rank we’ve observed—and the first time we’ve seen Hims back on the list in several weeks.
Litigation debate heats up. Analysts, investors, lawyers, doctors and everyone in between took to Twitter to weigh in on whether Novo Nordisk is going to sue Hims.
As Bayside noted in his special report a few months back, if Novo sues Hims for patent infringement, it would expose Novo’s semaglutide patents to risk of invalidation.
COMING TO THE HIMS HOUSE PODCAST ON MONDAY: We will host a patent attorney with pharma experience to break it all down 👀
ALSO! A Kalshi market was just created with the title “Will Novo Nordisk sue Hims & Hers Health?” It looks like the market is still “pending review”. I will post an update here if/when it goes live.
Catalysts
Any legal filings from Novo Nordisk or Hims
Lingo CGMs or other wearable partnerships?
More acquisitions still to come?
Move from the Russell 2000 to the Russell 1000 could drive institutional buying. Index reconstitution set for late June.
Pharma tariffs?
Partnership with Eli LillyAny incremental details on the Novo Nordisk roadmap
Top Tweets
